

Gary M. Nath (DC, NJ)
Harold L. Novick (DC, MD)
Todd L. Juneau (DC, IL)
Ross A. Epstein (CA)*

Irvjn A. Lavine (DC), Retired
Donald M. Sandler (MD), Retired*

Patent, Trademark and Copyright Causes
Unfair Competition, Trade Secrets,
Licensing and Litigation

*Practice limited to Matters and Proceedings before
Federal Courts and Agencies; not Admitted in DC

NATH & ASSOCIATES PLLC
Attorneys at Law
1030 Fifteenth Street, N.W.
Sixth Floor
Washington, D.C. 20005-1503

TELEPHONE (202) 775-8383
(202) 775-9393
FACSIMILE (202) 775-8396
(202) 822-9409
E-MAIL: IP@NATHLAW.COM
WEB: WWW.NATHLAW.COM

Michelle L. Harman
Lee C. Heiman
Jerald L. Meyer (VA)
Marvin C. Berkowitz (CA)
Tanya E. Harb
Joshua B. Goldberg (VA)
Todd W. Katz (IL)
Sheldon M. McGee (DC)
Alvin E. Tanenholz
François A. Pelaez PhD++

** Registered Patent Agent: not Admitted in DC
++ Limited Rep. at USPTO

RECEIVED
MAY 07 2002
6012900

REQUEST FOR

CONTINUED EXAMINATION (RCE)

TRANSMITTAL

Commissioner of Patents
Box RCE
Washington, D.C. 20231

Application No
Filing Date:
Title:

09/537,088
March 29, 2000
NOVEL INCLUSION COMPLEXES OF A HIGH POTENT
OPIOID PEPTIDE, PHARMACEUTICAL
COMPOSITIONS AND METHOD OF TREATMENT

Inventors:
Group Art Unit:
Examiner:
Atty Docket No:

DWIVEDI et al.
1653
J. Russel
82239

Sir:

This is a Request for Continued Examination (RCE) under 37 C.F.R. § 1.114 of the above-identified application.

Note: 37 C.F.R. § 1.114 is effective on May 29, 2000. If the above-identified application was filed prior to May 29, 2000, applicant may wish to consider filing a continued prosecution application (CPA) under 37 C.F.R. § 1.53(d) (PTO/SB/29) instead of a RCE to be eligible for the patent term adjustment provisions of the AIPA. See Changes to Application Examination and Provisional Application and Provisional Application Practice, Final Rule 65 Fed.Reg. 50092 9Aug. 16, 2000; Interim Rule, 65 Fed. Reg. 14865 (mar. 20, 2000), 1233 Off.Gaz. Pat. Office 47 (Apr. 11, 2000), which established RCE practice.

05/06/2002 AWOMDAF1 00000107 09537088

01 FC:179

740.00 OP

1. Submission required under 37 C.F.F. § 1.114

- a. ☒ Previously submitted
- i. ☒ Consider the amendments(s)/reply under 37 C.F.R. § 1.116 previously filed on 5/3/02.
 - ii. Consider the arguments in the Appeal Brief or Reply Brief previously filed on _____.
 - ii. Other _____.
- c. ☐ Enclosed
- i. ☐ Amendment/Reply
 - ii. ☐ Affidavit(s)/Declaration(s)
 - iii. ☐ Information Disclosure Statement (IDS)
 - iv. ☐ Other _____.

2. Miscellaneous


- a. _____ Suspension of action on the above-identified application is requested under 37 C.F.R. § 1.103(c) for a period of _____ months. (Period of suspension shall not exceed 3 months; Fee under 37 C.F.R. § 1.17(i) required)
- b. _____ Other _____.

3. Fees

(The RCE fee under 37 C.F.R. § 1.17(e) is required by 37 C.F.R. § 1.114 when the RCE is filed)

- a. ☒ The Director is hereby authorized to charge the following fees, or credit any overpayments, to Deposit Acct. No. 14-0112.
- i. ☒ RCE fee of \$ 740.00 required under 37 C.F.R. § 1.17 (e) is enclosed.
 - ii. ☐ Extension of time fee (37 C.F.R. §§ 1.136 and 1.17)
 - iii. ☐ Other _____.

Respectfully submitted,
NATH & ASSOCIATES PLLC


Harold L. Novick
Registration No. 26,011
Customer No. 20529

Date: 5/3/02
NATH & ASSOCIATES PLLC
1030 15TH Street NW - 6th Floor
Washington, D.C. 20005
HLN/JBG (RCE)



BOX PATENT

Attorney Docket No. 87239

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:) Group Art Unit: 1653
DWIVEDI et al.)
Serial No. 09/537,088)
Filed: March 29, 2000)
Examiner: J. RUSSEL

TECH CENTER 1600/2300

MAY 08 2002

RECEIVED

For: **NOVEL INCLUSION COMPLEXES OF A HIGH POTENT OPIOID PEPTIDE,
PHARMACEUTICAL COMPOSITIONS AND METHOD OF TREATMENT**

RESPONSE TO OFFICIAL ACTION

Commissioner for Patents
Washington, D.C. 20231

Sir:

This is in response to the Final Office Action having a mailing date of November 7, 2001, with the three month shortened statutory period to respond set to expire on February 7, 2002. A petition for a three-month extension of time and a check are filed herewith extending the period for response to May 7, 2002. Accordingly, this Response is timely filed.

In view of the following remarks, applicants respectfully request the Examiner to reconsider and withdraw the outstanding rejections and allow all claims pending in this application.

AMENDMENT

IN THE SPECIFICATION

Please amend the specification as indicated in Appendices A